We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

214 hedge funds and large institutions have $2.82B invested in Mirum Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 76 increasing their positions, 80 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $2.44B → $2.82B (+$375M)

1.35% more ownership

Funds ownership: 110.47%111.83% (+1.4%)

6% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 33

0% more funds holding

Funds holding: 214214 (0)

5% less repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 80

18% less funds holding in top 10

Funds holding in top 10: 119 (-2)

69% less call options, than puts

Call options by funds: $1.55M | Put options by funds: $5.06M

Holders
214
Holders Change
Holders Change %
0%
% of All Funds
2.82%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.12%
New
35
Increased
76
Reduced
80
Closed
33
Calls
$1.55M
Puts
$5.06M
Net Calls
-$3.51M
Net Calls Change
-$1.16M
Name Holding Trade Value Shares
Change
Change in
Stake
RHJA
51
Rice Hall James & Associates
California
$11.8M -$120K -2,703 -1%
EMFAT
52
Emerald Mutual Fund Advisers Trust
Pennsylvania
$11.1M +$9.69M +217,542 New
PM
53
Prosight Management
Texas
$10.2M -$6.38M -143,326 -42%
Wells Fargo
54
Wells Fargo
California
$10.1M +$7.32M +164,492 +489%
NCGI
55
Next Century Growth Investors
Minnesota
$9.69M -$223K -5,016 -3%
NIP
56
Nicholas Investment Partners
California
$9.39M +$509K +11,440 +7%
UBS Group
57
UBS Group
Switzerland
$9.29M -$2.38M -53,501 -23%
Two Sigma Investments
58
Two Sigma Investments
New York
$8.74M -$147K -3,312 -2%
Two Sigma Advisers
59
Two Sigma Advisers
New York
$8.72M -$1.57M -35,200 -17%
UBS AM
60
UBS AM
Illinois
$8.22M +$533K +11,972 +8%
AG
61
Algert Global
California
$8.11M +$4.12M +92,588 +139%
Qube Research & Technologies (QRT)
62
Qube Research & Technologies (QRT)
United Kingdom
$8.09M +$872K +19,594 +14%
Deutsche Bank
63
Deutsche Bank
Germany
$7.92M -$3.79M -85,117 -35%
Barclays
64
Barclays
United Kingdom
$7.88M +$3.28M +73,567 +90%
JF
65
Jump Financial
Illinois
$7.57M +$5.92M +132,866 +840%
NFT
66
Nan Fung Trinity
Hong Kong
$7.47M +$6.53M +146,765 New
PP
67
PDT Partners
New York
$7.4M +$351K +7,884 +6%
CSS
68
Cubist Systematic Strategies
Connecticut
$7.38M -$6.76M -151,937 -51%
SAM
69
Silvercrest Asset Management
New York
$6.92M
Ensign Peak Advisors
70
Ensign Peak Advisors
Utah
$6.82M
First Trust Advisors
71
First Trust Advisors
Illinois
$6.61M +$7.12K +160 +0.1%
HP
72
Highlander Partners
Texas
$6.26M
HWAM
73
Hennion & Walsh Asset Management
New Jersey
$6.25M -$1.09M -24,424 -17%
Wellington Management Group
74
Wellington Management Group
Massachusetts
$6.03M +$251K +5,647 +5%
PSC
75
Patient Square Capital
California
$5.77M -$129K -2,900 -2%

MIRM Hedge Fund Activity: Q2 2025 in Review

214 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q2 2025, worth a combined $2.82B — up 15% from $2.44B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new MIRM positions and 33 closed out — a net gain of 2 holders — while 76 added to existing stakes and 80 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $20.9M. The largest seller was Invesco, cutting an estimated $11.1M.

  • 214 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $2.82B of Mirum Pharmaceuticals stock for Q2 2025, up 15% quarter-over-quarter.
  • 35 funds opened new Mirum Pharmaceuticals positions in Q2 2025 and 33 closed out, a net change of +2 holders.
  • The largest Mirum Pharmaceuticals buyer in Q2 2025 was Janus Henderson Group, an estimated $20.9M added.
  • The largest Mirum Pharmaceuticals seller in Q2 2025 was Invesco, an estimated $11.1M sold.

Based on aggregated 13F filings for Q2 2025.